Richard S Blumberg

This inventor holds 26 USPTO granted patents and 31 published patent applications, plus 3 CIPO patents and 10 EPO patents, primarily in Immunotherapy Research. Top assignees: The Brigham and Women's Hospital, Inc., Brandeis University, The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2000-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Richard S Blumberg. Retrieved from https://idiyas.com/inventor/richard-s-blumberg

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 31)

% Patents Active = 61.5

CIPO Patents = 3 (Patent Applications = 8)

EPO Patents = 10 (Patent Applications = 22)

Average Co-Inventor Count = 2.8

ph-index = 8

Forward Citations = 802(Granted Patents)

Location History:

Chestnut Hill, MA (US) (2000 - 2014)
Waltham, MA (US) (2012 - 2020)
Weston, MA (US) (2020 - 2023)

Company Filing History:

21 out of 1,428

The Brigham and Women's Hospital, Inc.

The United States of America, as Represented by the Secretary, Department of Health and Human Services

7. 2 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 2000-2024

Loading Chart...

Areas of Expertise:

Anti-CEACAM1 Antibodies

FcRn Binding Peptides

Immune Response Modulation

Alpha-Fetoprotein Manipulation

Oxazole Compounds

Glycosphingolipids

T Cell Inhibitory Receptors

Colitis Treatment Methods

Therapeutic Transport

Cytotoxic T Lymphocyte Activity

Receptor Specific Transport

Immunogen Transport

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12173066 - Humanized and affinity-matured anti-CEACAM1 antibodies (2024-12-24),

2. 12110333 - Methods to manipulate alpha-fetoprotein (AFP) (2024-10-08),

3. 11591300 - Oxazole containing compounds as activators of IDO1 and AhR (2023-02-28),

4. 10822417 - Humanized affinity matured anti-FcRn antibodies (2020-11-03),

5. 10626175 - Humanized affinity matured anti-FcRn antibodies (2020-04-21),

6. 10588935 - FC receptor (FcRn) binding peptides and uses thereof (2020-03-17),

7. 10513540 - Modulation of the immune response (2019-12-24),

8. 10329315 - Glycosphingolipids and methods of use thereof (2019-06-25),

9. 10046023 - FC receptor (FcRn) binding peptides and uses thereof (2018-08-14),

10. 10035858 - Compositions and methods for modulating an immune response (2018-07-31),

11. 9689044 - Assays and methods to sequence microbes directly from immune complexes (2017-06-27),

12. 9556271 - Anti-CEACAM1 recombinant antibodies for cancer therapy (2017-01-31),

13. 9527890 - FC receptor (FcRn) binding peptides and uses thereof (2016-12-27),

14. 8821866 - Methods of treating and preventing colitis involving IL-13 and NK-T cells (2014-09-02),

15. 8232067 - Disrupting FCRN-albumin interactions (2012-07-31),

Title: Richard S Blumberg: Pioneering Innovations in Immunology and Antibody Therapeutics

Introduction:

Richard S Blumberg, a distinguished inventor based in Waltham, MA, US, is renowned for his groundbreaking work in the fields of immunology and antibody therapeutics. With an impressive portfolio of 24 patents, Blumberg has significantly contributed to advancements in medical science.

Latest Patents:

Blumberg's latest patents showcase his expertise in developing cutting-edge solutions for stimulating the immune system and treating various disorders. One of his recent inventions includes oxazole-containing compounds that act as activators of IDO1 and AhR, demonstrating novel methods for enhancing immune response in individuals. Additionally, his work on humanized affinity-matured anti-FcRn antibodies represents a promising avenue for addressing acute and chronic toxic exposure by targeting FcRn and human serum albumin binding.

Career Highlights:

Throughout his career, Blumberg has made significant strides in research and innovation. Having worked at prestigious institutions such as The Brigham and Women's Hospital and Brandeis University, he has established himself as a pioneer in the field of biotechnology. His patent portfolio stands as a testament to his dedication to pushing the boundaries of medical science.

Collaborations:

Blumberg has collaborated with esteemed professionals in the industry, including Neil E Simister and Wayne I Lencer. Together, they have shared insights, expertise, and passion for driving innovation in immunology and antibody-based therapeutics. These collaborations have resulted in groundbreaking inventions that have the potential to revolutionize the treatment of various diseases.

Conclusion:

In conclusion, Richard S Blumberg's contributions to the fields of immunology and biotechnology have been nothing short of exemplary. His innovative patents and collaborative efforts underscore his commitment to advancing medical research and improving healthcare outcomes. Blumberg's legacy as an inventor and researcher continues to inspire and pave the way for future innovations in the field.

Profile summary based on public USPTO records.